GO
Loading...

Medicine

More

  • LOS ANGELES/ LONDON April 11- Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

  • Mexican police issue 'ransom ware' virus warning Thursday, 10 Apr 2014 | 4:44 PM ET

    MEXICO CITY— Police in Mexico City have issued a warning about a new type of "ransom ware" virus that can take over computers' cameras and make the user think they are under surveillance. The Mexico City police department's cyber-crime unit says the virus infects computers, generally after they view or download sexually explicit material.

  • Hep C breakthrough     Thursday, 10 Apr 2014 | 2:53 PM ET

    CNBC contributor Barbara Ryan provides insight into new guidelines from the World Health Organization, which strongly endorses two new hepatitis c drugs.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • Maine Medicaid rules reduce narcotic prescriptions Thursday, 10 Apr 2014 | 12:01 PM ET

    PORTLAND, Maine— Maine's severe restrictions on opioid painkillers for Medicaid patients, requiring many to instead seek alternative pain management treatment for the past year, have sharply reduced the number of people obtaining highly addictive medications blamed for drug abuse and deaths around the nation.

  • MUMBAI, April 10- India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.

  • CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.

  • April 10- Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.

  • April 10- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

  • April 10- A two-drug combination being tested by Merck& Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

  • Bacon prices jump 10% after rash of baby pig deaths Wednesday, 9 Apr 2014 | 8:39 AM ET

    A new virus has killed millions of baby pigs in the U.S. in less than a year. The consequence? Bacon prices rising by more than ten percent.

  • FDA halts Halozyme's pancreatic cancer study Wednesday, 9 Apr 2014 | 8:32 AM ET

    April 9- Halozyme Therapeutics Inc said the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial. The company's shares fell about 3 percent to $8.06 in trading before the bell.

  • LONDON, April 9- The World Health Organisation wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.

  • 3 dozen possibly ill with Norovirus on cruise ship Tuesday, 8 Apr 2014 | 5:33 PM ET

    SAN FRANCISCO— Officials say more than three dozen people are possibly ill with the highly contagious Norovirus while onboard a cruise ship sailing to ports in California. Princess Cruises spokeswoman Karen Candy says about 37 passengers on the Crown Princess reported being sick while the ship was in San Francisco on Monday.

  • April 8- Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11 percent. The growing market for atypical antipsychotics for schizophrenia was worth $4.5 billion in the United States, Pops said.

  • *Working on more tiered pricing after deal with Egypt. LONDON, April 8- Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

  • April 8- Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. Alkermes success comes about a week after Australia- based Prana Biotechnology said its experimental drug to treat Alzheimer's disease failed a mid-stage study.

  • April 8- Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study.

  • April 6- Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said. The U.S. Food and Drug Administration has granted "breakthrough" status for palbociclib.

  • April 4- Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.

Most Popular Video

Monday, 21 Apr 2014 | 7:42 AM ET

Jon Steinberg, BuzzFeed, provides a preview of tech earnings and explains why Apple shares are flat.

Monday, 21 Apr 2014 | 7:32 AM ET

Boris Schlossberg, BK Asset Management; Ed Keon, Quantitative Management Associates; and Krishna Guha, ISI Group, discuss the strong euro, the play on the Japanese yen and whether the markets are fairly valued.

Monday, 21 Apr 2014 | 7:19 AM ET

Garvis Toler, Dealogic, discusses what's driving the increase in tech IPOs as Alibaba readies its public debut.